Literature DB >> 20849969

Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.

Fusako Waki1, Kazuhiro Masuoka, Takahiro Fukuda, Yoshinobu Kanda, Mika Nakamae, Kimikazu Yakushijin, Katsuhiro Togami, Kaichi Nishiwaki, Yasunori Ueda, Fumio Kawano, Masaharu Kasai, Koji Nagafuji, Maki Hagihara, Kazuo Hatanaka, Masafumi Taniwaki, Yoshinobu Maeda, Naoki Shirafuji, Takehiko Mori, Atae Utsunomiya, Tetsuya Eto, Hitoshi Nakagawa, Makoto Murata, Toshiki Uchida, Hiroatsu Iida, Kazuaki Yakushiji, Takuya Yamashita, Atsushi Wake, Satoshi Takahashi, Yoichi Takaue, Shuichi Taniguchi.   

Abstract

To evaluate whether rescue with cord blood transplantation (CBT) could improve the poor survival after graft failure (GF), we surveyed the data of 80 adult patients (median age, 51 years) who received CBT within 3 months of GF (primary 64, secondary 16), with fludarabine-based reduced-intensity regimens with or without melphalan, busulfan, cyclophosphamide, and/or 2-4 Gy total-body irradiation (TBI). A median number of 2.4 × 10(7)/kg total nucleated cells (TNC) were infused, and among the 61 evaluable patients who survived for more than 28 days, 45 (74%) engrafted. The median follow-up of surviving patients was 325 days, and the 1-year overall survival rate was 33% despite poor performance status (2-4, 60%), carryover organ toxicities (grade 3/4, 14%), and infections (82%) prior to CBT. Day 100 transplantation-related mortality was 45%, with 60% related to infectious complications. Multivariate analysis showed that the infusion of TNC ≥2.5 × 10(7)/kg and an alkylating agent-containing regimen were associated with a higher probability of engraftment, and that high risk-status at the preceding transplantation and grade 3/4 organ toxicities before CBT were associated with an increased risk of mortality. In conclusion, in an older population of patients, our data support the feasibility of CBT with a reduced-intensity conditioning regimen for GF.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849969     DOI: 10.1016/j.bbmt.2010.09.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.

Authors:  K Ishiyama; J Takeda; T Kondo; N Sugimoto; H Kawabata; T Kitano; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

2.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

3.  Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Authors:  Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

4.  Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells.

Authors:  M Kwon; C Martínez-Laperche; P Balsalobre; D Serrano; J Anguita; J Gayoso; J L Díez-Martín; I Buño
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

Review 5.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742

6.  Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT.

Authors:  J A Park; K N Koh; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo; H J Im
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

7.  Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Shigeo Fuji; Sachiko Seo; Junya Kanda; Toshimitsu Ueki; Fumihiko Kimura; Koji Kato; Naoyuki Uchida; Kazuhiro Ikegame; Makoto Onizuka; Ken-Ichi Matsuoka; Noriko Doki; Toshiro Kawakita; Yasushi Onishi; Shingo Yano; Takahiro Fukuda; Minoko Takanashi; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata
Journal:  Bone Marrow Transplant       Date:  2020-02-12       Impact factor: 5.483

8.  Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

Authors:  J Kanda; M E Horwitz; G D Long; C Gasparetto; K M Sullivan; J P Chute; A Morris; T Hennig; Z Li; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-08-01       Impact factor: 5.483

9.  Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure.

Authors:  Sakurako Suma; Yasuhisa Yokoyama; Haruka Momose; Kenichi Makishima; Yusuke Kiyoki; Tatsuhiro Sakamoto; Manabu Kusakabe; Takayasu Kato; Naoki Kurita; Hidekazu Nishikii; Mamiko Sakata-Yanagimoto; Naoshi Obara; Yuichi Hasegawa; Shigeru Chiba
Journal:  Intern Med       Date:  2021-11-20       Impact factor: 1.282

10.  Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen.

Authors:  Annalisa Ruggeri; Myriam Labopin; Maria Pia Sormani; Guillermo Sanz; Jaime Sanz; Fernanda Volt; Gerard Michel; Franco Locatelli; Cristina Diaz De Heredia; Tracey O'Brien; William Arcese; Anna Paola Iori; Sergi Querol; Gesine Kogler; Lucilla Lecchi; Fabienne Pouthier; Federico Garnier; Cristina Navarrete; Etienne Baudoux; Juliana Fernandes; Chantal Kenzey; Mary Eapen; Eliane Gluckman; Vanderson Rocha; Riccardo Saccardi
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.